AT2101 clinical trials
Also written AT2101 and afegostat tartrate.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses AT2101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses AT2101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement TherapyCompletedPhase 2Amicus TherapeuticsNCT00433147Written as Afegostat tartrateHow we know
- A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher PatientsCompletedPhase 2Amicus TherapeuticsNCT00813865Written as afegostat tartrateHow we know
- A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher DiseaseCompletedPhase 2Amicus TherapeuticsNCT00446550Written as afegostat tartrateHow we know
- A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101TerminatedPhase 1Amicus TherapeuticsNCT00875160Written as AT2101How we know